While semaglutide remains on the shortage list, Novo Nordisk noted last week that the last remaining dose in short supply -- ...
While some GLP-1s are approved for patients age 12 and older, only a few telehealth companies will prescribe them to children.
Danish pharmaceutical giant Novo Nordisk sees a significant increase in profits and sales despite production constraints.
Health-care companies ticked up amid mixed earnings and consolidation prospects. ADRs of Danish drug giant Novo Nordisk fell after sales of its blockbuster Wegovy weight-loss drug failed to surpass ...
Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
Novo Nordisk's Wegovy sales exceed forecasts, boosting shares by 9%. U.S. demand remains high with expanded supply plans and ...
Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.
On Wednesday, Novo Nordisk A/S (NYSE:NVO) reported third-quarter 2024 sales of 71.311 billion Danish kroner (around $10.3 ...
Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...